Brokers

Brokers Set Expectations for Checkpoint Therapeutics, Inc.’s Q2 2022 Earnings (NASDAQ:CKPT)


Checkpoint Therapeutics, Inc. (NASDAQ:CKPTGet Rating) – Equities research analysts at B. Riley issued their Q2 2022 earnings per share estimates for shares of Checkpoint Therapeutics in a research note issued to investors on Tuesday, May 17th. B. Riley analyst J. Walsh expects that the company will post earnings per share of ($0.22) for the quarter. B. Riley also issued estimates for Checkpoint Therapeutics’ Q3 2022 earnings at ($0.23) EPS, Q4 2022 earnings at ($0.31) EPS, FY2022 earnings at ($0.98) EPS, FY2023 earnings at ($1.14) EPS, FY2024 earnings at ($0.66) EPS, FY2025 earnings at $0.01 EPS and FY2026 earnings at $1.42 EPS.

Several other brokerages have also recently issued reports on CKPT. HC Wainwright raised their target price on shares of Checkpoint Therapeutics from $17.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, January 25th. LADENBURG THALM/SH SH boosted their target price on shares of Checkpoint Therapeutics from $20.00 to $26.00 in a report on Wednesday, January 26th. Finally, Cantor Fitzgerald boosted their target price on shares of Checkpoint Therapeutics from $16.00 to $20.00 in a report on Wednesday, January 26th.

Shares of CKPT opened at $1.39 on Friday. The company has a market capitalization of $125.92 million, a P/E ratio of -1.64 and a beta of 1.71. The firm has a 50 day moving average of $1.51 and a 200 day moving average of $2.33. Checkpoint Therapeutics has a twelve month low of $0.96 and a twelve month high of $4.64.

Checkpoint Therapeutics (NASDAQ:CKPTGet Rating) last posted its quarterly earnings results on Thursday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.06). Checkpoint Therapeutics had a negative net margin of 26,592.46% and a negative return on equity of 173.15%.

Several institutional investors have recently made changes to their positions in the company. Level Four Advisory Services LLC acquired a new position in Checkpoint Therapeutics in the 4th quarter valued at $31,000. Eqis Capital Management Inc. purchased a new stake in shares of Checkpoint Therapeutics in the 1st quarter worth about $33,000. JPMorgan Chase & Co. boosted its position in shares of Checkpoint Therapeutics by 73,468.4% in the 4th quarter. JPMorgan Chase & Co. now owns 13,978 shares of the company’s stock worth $43,000 after buying an additional 13,959 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Checkpoint Therapeutics by 22.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 13,941 shares of the company’s stock valued at $46,000 after acquiring an additional 2,541 shares during the last quarter. Finally, Truist Financial Corp increased its stake in shares of Checkpoint Therapeutics by 29.2% during the 3rd quarter. Truist Financial Corp now owns 14,169 shares of the company’s stock valued at $47,000 after acquiring an additional 3,205 shares during the last quarter. 11.87% of the stock is currently owned by institutional investors and hedge funds.

In other Checkpoint Therapeutics news, CFO William Garrett Gray sold 38,197 shares of Checkpoint Therapeutics stock in a transaction dated Thursday, March 10th. The shares were sold at an average price of $1.89, for a total transaction of $72,192.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO James F. Oliviero III sold 86,353 shares of the firm’s stock in a transaction that occurred on Monday, April 4th. The shares were sold at an average price of $1.79, for a total transaction of $154,571.87. Following the completion of the transaction, the chief executive officer now directly owns 2,873,291 shares of the company’s stock, valued at approximately $5,143,190.89. The disclosure for this sale can be found here. Insiders sold 145,808 shares of company stock worth $258,864 in the last quarter. Company insiders own 6.10% of the company’s stock.

About Checkpoint Therapeutics (Get Rating)

Checkpoint Therapeutics, Inc, clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company’s lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.

Recommended Stories

Earnings History and Estimates for Checkpoint Therapeutics (NASDAQ:CKPT)



Receive News & Ratings for Checkpoint Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Checkpoint Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.